You need to be logged in to view this video
Join John McCamant, editor of the Medical Technology Stock Letter, to discover how from vaccines to new drugs, Covid-19 shines the spotlight biotech's ability to provide solutions.
John McCamant
Medical Technology Stock Letter,
Editor
John McCamant joined the leading investment newsletter, Medical Technology Stock Letter, as an associate editor in 1987 and was named editor in August 2000. He has spent over 35 years on the front lines of biotechnology investing. In his previous role as an equities analyst for the American Healthcare fund, Mr. McCamant uncovered investment opportunities and guided investment strategy.
Trending Now
Filter By Category
Filter By Keywords
Loading...